News & Events

Corporate Presentation
More information is coming soon.
News Releases
NEW YORK , May 16, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, announced today that ELZONRIS (tagraxofusp) clinical data in chronic myelomonocytic

Additional Formats

Net revenue for ELZONRIS was $5.05 million for the first quarter Conference call and live webcast scheduled for today at 8:00 AM ET NEW YORK , May 10, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and

Additional Formats

NEW YORK , May 08, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, announced today that the company will host a conference call and live webcast on

Additional Formats

NEW YORK , April 25, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, announced today that the pivotal trial results of ELZONRIS™ (tagraxofusp), a

Additional Formats

NEW YORK , March 18, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, announced today that Ivan Bergstein , M.D., Stemline’s CEO, was selected to

Additional Formats

Upcoming Events
More events are coming soon.